CRISPR and Genome Editing – Products

This compendium explores analytical advancements in cell and gene therapy, highlighting the latest tools and strategies for ensuring therapeutic quality.

eXmoor pharma, and Virica Biotech Inc. (“Virica”), announced a new project funded in part through a joint Canada-UK government biomanufacturing collaboration.

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announces they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs).

BioPORTER® protein delivery reagent from AMSBIO is proven to efficiently transport functionally active proteins directly into living cells eliminating the traditional DNA transfection, transcription, and protein translation process.

Vericheck ddPCR empty-full capsid kit combines measuring viral titer and capsid titer, providing a high-precision assessment for critical quality attributes of both protein and DNA in droplets.

License agreement provides Université de Montréal access to CRISPR gene editing technology for use across its platform services.

A novel enzyme developed by research scientists at Promega Corporation will virtually eliminate confounding stutter artifacts in forensic DNA analysis.

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced the signature of a long-term commercial supply agreement for CASGEVY® (exagamglogene autotemcel).

Quell Therapeutics Ltd (“Quell” or “the Company”), and eXmoor pharma (“eXmoor”), announce a strategic partnership for the manufacture of multiple autologous engineered CAR-Treg cell therapies in Quell’s pipeline targeting autoimmune diseases.

Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology.